@article{c349e0eda8f04c25885906e035476639,
title = "Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD)",
abstract = "Background: Decision aids (DAs) can improve knowledge for prostate cancer treatment. However, the relative effects of DAs delivered within the clinical encounter and in more diverse patient populations are unknown. A multicenter cluster randomized controlled trial with a 2×2 factorial design was performed to test the effectiveness of within-visit and previsit DAs for localized prostate cancer, and minority men were oversampled. Methods: The interventions were delivered in urology practices affiliated with the NCI Community Oncology Research Program Alliance Research Base. The primary outcome was prostate cancer knowledge (percent correct on a 12-item measure) assessed immediately after a urology consultation. Results: Four sites administered the previsit DA (39 patients), 4 sites administered the within-visit DA (44 patients), 3 sites administered both previsit and within-visit DAs (25 patients), and 4 sites provided usual care (50 patients). The median percent correct in prostate cancer knowledge, based on the postvisit knowledge assessment after the intervention delivery, was as follows: 75% for the pre+within-visit DA study arm, 67% for the previsit DA only arm, 58% for the within-visit DA only arm, and 58% for the usual-care arm. Neither the previsit DA nor the within-visit DA had a significant impact on patient knowledge of prostate cancer treatments at the prespecified 2.5% significance level (P =.132 and P =.977, respectively). Conclusions: DAs for localized prostate cancer treatment provided at 2 different points in the care continuum in a trial that oversampled minority men did not confer measurable gains in prostate cancer knowledge.",
keywords = "decision aids, knowledge, prostate cancer, shared decision-making",
author = "Tilburt, {Jon C.} and David Zahrieh and Pacyna, {Joel E.} and Petereit, {Daniel G.} and Kaur, {Judith S.} and Rapkin, {Bruce D.} and Grubb, {Robert L.} and Chang, {George J.} and Morris, {Michael J.} and Kovac, {Evan Z.} and Babaian, {Kara N.} and Sloan, {Jeff A.} and Basch, {Ethan M.} and Peil, {Elizabeth S.} and Dueck, {Amylou C.} and Novotny, {Paul J.} and Paskett, {Electra D.} and Buckner, {Jan C.} and Joyce, {Daniel D.} and Montori, {Victor M.} and Frosch, {Dominick L.} and Volk, {Robert J.} and Kim, {Simon P.}",
note = "Funding Information: Daniel G. Petereit reports grant support from the Bristol‐Myers Squibb Foundation, the Irving A. Hansen Foundation, the Ralph Lauren Pink Pony Foundation, and the National Institutes of Health (1R01CA240080‐01); consulting fees from Boston Scientific; payments or honoraria from Boston Scientific, the University of California San Francisco, the Mayo Clinic, and the University of Pennsylvania; legal consultancy for brachytherapy cases; and a leadership role with the American Brachytherapy Society. George J. Chang reports consulting fees from Medicaroid and participation on boards for J&J and 11 Health. Ethan M. Basch reports consulting fees from AstraZeneca, Carevive Systems, Navigating Cancer, and Sivan Healthcare. Michael J. Morris is an uncompensated consultant for Bayer, Novartis, Advanced Accelerator Applications, Janssen, and Lantheus; is a compensated consultant for ORIC, Curium, Athenex, the National Comprehensive Cancer Network, and Exelixis; reports participation on boards for Curium, Athenex, Exelixis, AstraZeneca, and Amgen; and receives institutional funding for clinical trials from Bayer, Endocyte, Progenics, Corcept, Roche/Genentech, Celgene/Bristol‐Myers Squibb, and Janssen. None of his disclosures are related to this work. Electra D. Paskett is a multiple principal investigator on a grant to her institution from the Merck Foundation and on another grant from Pfizer, and she also receives grant funding to her institution from the Breast Cancer Research Foundation. None of her disclosures are related to this work. Victor M. Montori reports that he works at the Knowledge and Evaluation Research Unit of the Mayo Clinic and conducts research into shared decision‐making; often, shared decision‐making tools are produced that are placed in the public domain and are free to use and that produce no income to the research unit or to him personally. Dominick L. Frosch reports consulting fees paid to his former employer (Sutter Health) by the Mayo Clinic/National Institutes of Health. The other authors made no disclosures. Funding Information: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers UG1CA189823 (Alliance for Clinical Trials in Oncology NCI Community Oncology Research Program grant); UG1CA189848, UG1CA233270, UG1CA233290, UG1CA233329, UG1CA233331, UG1CA233373, UG1CA232760, and R01 MD008934 (Jon C. Tilburt, Joel E. Pacyna, Judith S. Kaur, and Simon P. Kim); and U10CA180820, UG1CA189830, and UG1CA189854 (ECOG‐ACRIN). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health ( https://acknowledgments.alliancefound.org ). Publisher Copyright: {\textcopyright} 2021 American Cancer Society",
year = "2022",
month = mar,
day = "15",
doi = "10.1002/cncr.34062",
language = "English (US)",
volume = "128",
pages = "1242--1251",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",
}
